Prevalence of autosomal dominant polycystic kidney disease in the European Union.
about
Autosomal dominant polycystic kidney disease: recent advances in clinical managementHealthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy.Functional Budd-Chiari Syndrome Associated With Severe Polycystic Liver Disease.Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney diseaseMethodological issues in clinical trials of polycystic kidney disease: a focused review.Biliary Tract and Liver Complications in Polycystic Kidney Disease.PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.Molecular diagnosis of autosomal dominant polycystic kidney disease.Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition.A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan.Cystic Kidney Diseases From the Adult Nephrologist's Point of View.Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence.Applications of kidney organoids derived from human pluripotent stem cells.Case report: a thiazide diuretic to treat polyuria induced by tolvaptan.High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney DiseaseUpdated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney DiseaseClinical Features of 167 Inpatients with Autosomal Dominant Polycystic Kidney Disease at a Single Center in China
P2860
Q28079782-5F7BE6EB-A1FC-4030-9273-6BE24D7226F8Q33627670-9B32A061-2A90-40C0-94AF-C0D9F93E23D4Q33783831-8BE8A3EF-B7DD-46B0-8D9F-4D9AB73DBE71Q36380634-3B67AD8C-9894-41D5-B773-7B9635CCFD71Q38794129-B600A8B6-DF3B-4454-8212-916B49AC4DF0Q38808055-6276F1C2-188D-4F54-B822-C5005C408E68Q38868452-7774AB5A-F556-4BCA-868F-4473AE258DB7Q39228045-896126E5-BE82-4137-8B24-C61A91B82B2BQ39445724-C86A7593-E3B2-45E6-97F2-8BCF02E6B0F7Q41247634-CDC90138-8AE2-456C-B783-804A67251A7EQ47141485-10A7EAA1-1158-4509-89D9-827731B0C621Q47781166-41307F8C-F0B1-4569-9538-3EF86487DF95Q48235375-0038F4C7-C298-4E60-8B90-E577A909E8FAQ49198447-B7D6466F-B44E-43EC-87A4-B677B044FEBFQ49769689-BDDA060B-037A-4347-A506-9BEB4ED1EE72Q52330435-6355C798-E98D-4F39-9C8C-E778956F78F5Q55260294-51148C6C-DDD3-4017-B5F6-6AB7546A689EQ55426316-77AA475F-741F-4E14-AE62-972B3226F155Q55501159-F49C19A0-3AA2-4C80-8759-181B0C65073DQ56978067-AEA33790-14B9-4F70-86C1-9EA305A47F6FQ57815283-DC283073-85EA-4850-8B80-D5A493B9A702Q58735929-3001CA74-4328-45B8-8D30-05B3D3632EA9
P2860
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
@en
type
label
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
@en
prefLabel
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
@en
P2093
P2860
P356
P1476
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
@en
P2093
Andrew J Makin
Anthony K Hall
Cynthia J Willey
Frank S Czerwiec
Holly B Krasa
Jaime D Blais
P2860
P304
P356
10.1093/NDT/GFW240
P407
P577
2017-08-01T00:00:00Z